Business
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- ...
About this update from Prime Drink Group Corp
[{"type":"text","content":"Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates\n\n\n\n\n -- Initial data from Phase 1/2 trial of PM359 for p47\n \n\n\n phox\n \n\n\n CGD expected in 2025 --\n \n\n\n\n -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 --\n \n\n\n\n -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 --\n \n\n\n CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) --  Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2025 and provided a business update.\n \n\n “We recently unveiled our AATD program, further demonstrating our commitment to building a liver franchise of Prime Editors designed to cure major genetic diseases,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. “Both our Wilson’s Disease and AATD programs are advancing through preclinical development, and we look forward to initiating clinical trials in both indications in 2026. In addition, we remain on track to report initial data from our Phase 1/2 trial of PM359 in CGD this year, and continue to progress our efforts in CF.”\n \n\n Dr. Gottesdiener continued, “While PM359 leverages a different delivery mechanism from our programs in liver and lung diseases, we believe our forthcoming CGD data could provide important readthrough across our pipeline. If positive, these data would demonstrate the potential of Prime Editing as a powerful and differentiated technology, potentially capable of offering curative benefit to patients following a single treatment. We remain committed to executing with focus and discipline as we approach these first in-human data, which we hope will mark a key inflection point on our path to sustained growth.”\n \n\n\n Prime Medicine’s Pipeline:\n \n\n\n Prime Medicine is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease (CGD) and X-linked CGD; lipid nanoparticle (LNP) Prime Editors for the treat...